Home Featured Page 166

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Filament Health Announces Second Patent Issuance

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership...

COMPASS Pathways and partners launch The Centre for Mental Health Research...

Awakn Life Sciences Announces Closing of Private Placement

PT303 – Adam Bramlage – Cannabis, Microdosing, and Our Evolutionary Connection...

Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

PT302 – Dr. Adele Lafrance – Vital Psychedelic Conversations

How Can We Apply Harm Reduction to HPPD?

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London...

Green Market Report – Are Psychedelics Leaving Minorities Behind?

1...165166167...292 Page 166 of 292

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Filament Health Announces Second Patent Issuance

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership...

COMPASS Pathways and partners launch The Centre for Mental Health Research...

Awakn Life Sciences Announces Closing of Private Placement

PT303 – Adam Bramlage – Cannabis, Microdosing, and Our Evolutionary Connection...

Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

PT302 – Dr. Adele Lafrance – Vital Psychedelic Conversations

How Can We Apply Harm Reduction to HPPD?

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London...

Green Market Report – Are Psychedelics Leaving Minorities Behind?

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY